Drug Watch: Agents in late-stage development for the treatment of hepatitis B and C virus infections (October 2008) (PDF)

If approved, elinzanetant would be another non-hormonal option for menopausal women seeking hot flash relief.

Sanjula Jain of Trilliant Health talks about how employers are best positioned to demand value for money from the U.S. healthcare system.

UnitedHealthcare is adding deductibles to Part D prescriptions on certain formulary tiers as a result of plan design changes from the Inflation Reduction Act.

Dry eye disease affects up to 15% of the U.S. population and is one of the largest markets in the ophthalmology field.

Otulfi is the fourth Stelara biosimilar to be approved by the FDA.

Blue Shield of California is purchasing Idacio for a net price of $525 per monthly dose, and most plan members will pay $0 out of pocket.